Molecular Basis of p53-induction to DNA Damage Essential to p53 activation is to abrogate the ability of MDM2 to target p53 for inactivation. Despite extensive information, many important aspects regarding MDM2-mediated p53 degradation and its regulation remain not fully understood, which is in large part attributable to the complexity of the process that is regulated by a wide array of signaling pathways. Our previous study identified the residues 92-112 of p53 as an important sequence affecting p53 stability. Further experiments uncovered CRP2 as one of the proteins bond to the p53 sequence. Significantly, a role for CRP2 in the regulation of p53 stability was suggested by our preliminary study and is also supported by published reports. Other work from our laboratory identified the acidic domain of MDM2 as another region, in addition to the ring finger domain, essential for MDM2 to target p53 for full ubiquitination. However, how the acidic domain contributes to MDM2-mediated p53 degradation remains unclear. Recent genetic studies have demonstrated both MDM2 and MDMX as essential negative regulators of p53 it is unknown, however, why neither mdm2 nor mdmx can compensate for the loss of the other. The mutual functional dependency between MDM2 and MDMX, as demonstrated by our recent studies, suggests that the MDM2/MDMX heterocomplex may function as an integral unit in targeting p53 for degradation. By choosing the p53-MDM2/MDMX module as the focal point of the investigation, we propose to extend our previous studies to three specific aims for elucidating the mechanisms underlying MDM2- mediated p53 degradation and the p53 response to stress.
The specific aims are: 1. Assess CRP2, a protein that binds to the residues 92-112 of p53, for its role in Mdm2-targeted p53 ubiquitination/degradation and the p53 response to stress. 2. Investigate a role for the MDM2 acidic domain in p53 ubiquitination/degradation. 3. Functionally characterize the MDM2/MDMX heterocomplex in p53 regulation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA085679-06
Application #
7103582
Study Section
Cell Development and Function Integrated Review Group (CDF)
Program Officer
Pelroy, Richard
Project Start
2000-04-01
Project End
2009-05-31
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
6
Fiscal Year
2006
Total Cost
$279,054
Indirect Cost
Name
Harvard University
Department
Genetics
Type
Schools of Public Health
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Kuser-Abali, Gamze; Gong, Lu; Yan, Jiawei et al. (2018) An EZH2-mediated epigenetic mechanism behind p53-dependent tissue sensitivity to DNA damage. Proc Natl Acad Sci U S A 115:3452-3457
de Polo, Anna; Luo, Zhongling; Gerarduzzi, Casimiro et al. (2017) AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex. J Mol Cell Biol 9:154-165
de Polo, Anna; Vivekanandan, Varunika; Little, John B et al. (2016) MDMX under stress: the MDMX-MDM2 complex as stress signals hub. Transl Cancer Res 5:725-732
Liu, X-S; Liu, Z; Gerarduzzi, C et al. (2016) Somatic human ZBTB7A zinc finger mutations promote cancer progression. Oncogene 35:3071-8
Yang, M; Lewinska, M; Fan, X et al. (2016) PRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis. Oncogene 35:5527-5538
Qi, Min; Ganapathy, Suthakar; Zeng, Weiqi et al. (2015) UXT, a novel MDMX-binding protein, promotes glycolysis by mitigating p53-mediated restriction of NF-?B activity. Oncotarget 6:17584-93
Liu, Xue-Song; Little, John B; Yuan, Zhi-Min (2015) Glycolytic metabolism influences global chromatin structure. Oncotarget 6:4214-25
Liu, Xue-Song; Genet, Matthew D; Haines, Jenna E et al. (2015) ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. Mol Cancer Res 13:1206-17
Yang, M; Yuan, Z-M (2015) A novel role of PRR14 in the regulation of skeletal myogenesis. Cell Death Dis 6:e1734
Ganapathy, Suthakar; Xiao, Shaowen; Yang, Mei et al. (2014) A low-dose arsenic-induced p53 protein-mediated metabolic mechanism of radiotherapy protection. J Biol Chem 289:5340-7

Showing the most recent 10 out of 30 publications